BioSpace News Archive

“After working in several nursing environments, I have encountered patients who continue to develop pressure ulcers despite multiple prophylactic methods and continuous skin observation,” said an inventor from DeWitt, Ark. “I wanted to develop an invention that would provide a simple, reusable and inexpensive alternative to current standards of practice to help all healthcare professionals and individuals decrease the incidence of pressure ulcers.”

Funding from the Pancreatic Cancer Action Network Contributes to Novel Science Published Today in the Journal Nature Medicine

As a leader in Bariatric surgery and non-surgical weight-loss procedures, New York Bariatric Group is announcing they will be the first Bariatric practice to offer the newly FDA-approved Obalon Navigation System to their patients starting in March 2019.

One Call, the nation’s leading provider of specialized healthcare solutions for the workers’ compensation industry, announced today that it has finalized a financial transaction resulting in an additional $150 million of liquidity over the next five years.

“I use ABG kits with my work as a respiratory therapist,” said an inventor from Lodi, Calif. “I thought that there had to be a better way to keep ABG cold.”

“I wanted to create an improved way to protect children and prevent other family members or visitors from accessing medications in the medicine cabinet,” said an inventor, from Winters, Calif., “so I invented the SECURE MEDICINE CABINET.”

AMPAC Fine Chemicals (AFC) is pleased to announce that effective today Mr. Chris Conley will assume the added responsibilities as Vice President, Human Resources in addition to his position as Vice President, Safety, Health and Environment (SH&E).

Neovasc Inc. announced that its Tiara™ transcatheter mitral valve replacement device was featured in an update presentation at the Cardiovascular Research Technologies meeting being held March 2-5, 2019 in Washington, DC.

Almirall S.A. (ALM) announced that it has entered into a definitive agreement with Celling Biosciences, based in Austin (Texas), to divest ThermiGen for an undisclosed amount.

Breckenridge Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Imatinib Mesylate Tablets, generic for Gleevec® Tablets by Novartis.